Oncocyte (NASDAQ:IMDX – Get Free Report) and Sera Prognostics (NASDAQ:SERA – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.
Volatility & Risk
Oncocyte has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.
Profitability
This table compares Oncocyte and Sera Prognostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncocyte | -2,955.63% | N/A | -107.52% |
| Sera Prognostics | -47,475.72% | -46.71% | -34.06% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncocyte | 1 | 0 | 2 | 0 | 2.33 |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
Oncocyte presently has a consensus target price of $10.50, indicating a potential upside of 153.62%. Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 158.22%. Given Sera Prognostics’ stronger consensus rating and higher probable upside, analysts plainly believe Sera Prognostics is more favorable than Oncocyte.
Valuation and Earnings
This table compares Oncocyte and Sera Prognostics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncocyte | $4.05 million | 33.45 | -$50.22 million | ($1.49) | -2.78 |
| Sera Prognostics | $80,000.00 | 1,050.36 | -$31.93 million | ($0.67) | -3.18 |
Sera Prognostics has lower revenue, but higher earnings than Oncocyte. Sera Prognostics is trading at a lower price-to-earnings ratio than Oncocyte, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
55.3% of Oncocyte shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Comparatively, 11.3% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Sera Prognostics beats Oncocyte on 8 of the 15 factors compared between the two stocks.
About Oncocyte
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.
